The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | Comparing outcomes of 10-day decitabine with venetoclax vs. chemotherapy in AML based on fitness
Abhishek Maiti, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase II study comparing outcomes of older acute myeloid leukemia (AML) patients receiving DEC10-VEN vs. intense chemotherapy, overall and after stratification by ‘fitness’ for intense chemotherapy using a validated treatment-related mortality score. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
